pill bottles

The Experimental Therapeutics (ET) Program’s research has a strong clinical and translational orientation, aligned along two main research themes:

  • Drug discovery and delivery
  • Clinical research

Within those themes, the program has these specific aims:

  • Providing new approaches to individualized cancer treatment such as targeted drug delivery systems, novel chemotherapeutics, improved imaging and image-guided techniques, and the most up-to-date clinical treatments via clinical trials
  • Fostering translation of discoveries between the laboratory and clinic through collaborations and scientific synergy among HCI members
  • Promoting specialized initiatives in quantitative, molecular, and pre-clinical imaging
  • Developing and executing investigator-initiated therapeutic, imaging, and imaging-guided clinical trials to establish new treatments for patients

Program Membership

HCI Cancer Center members enjoy a variety of benefits, including eligibility for leadership roles in the Center, institutional funding opportunities, and scientific/administrative support.

News Highlights from the Experimental Therapeutics Program

Committed to a Positive and Lasting Impact: The Engelstad Foundation
Sep 18, 2020

Committed to a Positive and Lasting Impact: The Engelstad Foundation

Samuel Cheshier, MD, PhD, and the Neurologic Cancers Center team at Huntsman Cancer Institute are working to find better treatments for brain cancer, particularly pediatric brain cancer. Many primary brain tumors are incurable from the start, and currently, none are curable once they recur. The need for novel, effective therapies is critical. In 2020, the Engelstad Foundation funded a $100,000 grant at HCI to study a potential immunotherapy treatment for pediatric brain tumors.... Read More

Research Advancing Individualized Treatment for Metastatic Prostate Cancers
Apr 24, 2020

Research Advancing Individualized Treatment for Metastatic Prostate Cancers

Prostate cancer is the second most common cancer for men in the United States. About one man in nine will be diagnosed with the disease at some point in his life. A study recently published in The Lancet’s EBioMedicine Journal describes new insights into how unique genetic traits of metastatic prostate tumors that are shed into the blood of cancer patients can be used for applying to the care of and potential molecularly targeted treatments in individual patients. ... Read More

Oncological Sciences
Read More